AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 282 min read$MBRX

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition

Original reporting
SEC EDGAR 8-K
Published Sep 28, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 11:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MBRX
Bullish
medium confidence
Mentioned
$MBRX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MBRXBullishMed
01

Why it matters

The cardiac safety publication addresses a major risk factor for anthracyclines, potentially unlocking further trial enrollment and financing.

02

Market read

First‑time disclosure of safety data could shift investor sentiment and affect MBRX valuation.

03

What to watch

Future FDA review timing and competitive landscape could moderate impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Moleculin Biotech (NASDAQ: MBRX) is a Phase 2/3 oncology company developing Annamycin, a re‑engineered anthracycline.

Company-level read

Ticker impact

$MBRXBullishMedium confidence
Context

Moleculin Biotech announced publication of a peer‑reviewed cardiac safety analysis showing no cardiotoxicity for Annamycin in 90 patients.

Expected impact

likely upward pressure as investors reassess safety concerns

Evidence & confidence

First disclosure of safety data removes a key development hurdle, encouraging buying interest.

Market effects

Sector

May boost confidence in anthracycline‑based oncology pipelines.

Regional

Limited to U.S. biotech sector.

Global

Reinforces safety profile trends for liposomal chemotherapies worldwide.

Counterpoint

What could challenge this read

Safety data may be insufficient to change valuation without efficacy data.

Key entities

  • company
    Moleculin Biotech, Inc.

    Developer of Annamycin and other oncology candidates.

  • institution
    Cleveland Clinic Cardio‑Oncology Lab

    Independent evaluator of the cardiac safety data.

Read at source← All news

Related articles

SEP 29
$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto

SEC EDGAR 8-K2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data

Moleculin Biotech (MBRX) published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, showing no cardiotoxicity in 90 patients treated with Annamycin across five trials. The study, evaluated by Cleveland Clinic, found no significant changes in left ventricular ejection fraction (LVEF) and no treatment-related cardiotoxicity. Annamycin is being evaluated in the MIRACLE trial for relapsed or refractory AML.

rttnews.com2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis

Moleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.

rttnews.com2 min
SEP 25
$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin ’ s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-medi

SEC EDGAR 8-K1 min
AUG 31
$MBRXMedAI 8/10

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Moleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.

stocktwits.com2 min